Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study
Current Oncology · 2025
DOI: 10.3390/curroncol32040187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Sneha Sura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ontada, Boston, MA 02110, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EMD Serono, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100004755), Pfizer, EMD Serono.
Abstract (Originalsprache)
Avelumab first-line maintenance (1LM) is approved for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who do not have disease progression after platinum-based chemotherapy (PBC). This retrospective study describes real-world treatment patterns and clinical outcomes in patients with la/mUC who initiated first-line (1L) systemic treatments, including avelumab 1LM, within iKnowMed, the US community oncology electronic health records database, between 1 December 2019 and 30 November 2023 and followed through 28 February 2024. In total, 1658 patients with la/mUC initiated 1L treatment: immuno-oncology (IO) monotherapy (41.2%), PBC only (32.4%), PBC followed by avelumab 1LM (11.2%), and other treatments (15.1%). The median OS (95% CI) from the start of 1L treatment was 20.4 (13.8, 30.0), 11.0 (8.5, 14.5), and 14.6 (12.6, 17.3) months for cisplatin-based only, carboplatin-based only, and IO monotherapy, respectively. Among the overall population, 36.1% and 11.8% of patients received second-line (2L) and third-line treatment, respectively. The median (95% CI) OS from the start of avelumab 1LM was 18.5 (13.8, 23.8) months. After discontinuation of avelumab 1LM, 43.5% received 2L treatment, and 59.3% of those received enfortumab vedotin (EV); the median (95% CI) OS from start of 2L EV was 12.7 (7.2, 16.5) months. Survival outcomes among patients treated with avelumab 1LM and 2L EV are consistent with respective clinical trials and other real-world studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ontada, Boston, MA 02110, USA.
- Rocky Mountain Cancer Centers, Littleton, CO 80120, USA.
- EMD Serono, Inc., Boston, MA 02210, USA, an affiliate of Merck KGaA.
ORCID-Profile: Manojkumar Bupathi, Valerie Morris
Förderung
- EMD Serono, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100004755)
- Pfizer
- EMD Serono
- Merck
Zitieren
APA
Sura, S., Bupathi, M., Morris, V., Conkling, P., Todoroff, K., Bhanegaonkar, A., & Ike, C. (2025). Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study. Current Oncology. https://doi.org/10.3390/curroncol32040187
Vancouver
Sura S, Bupathi M, Morris V, Conkling P, Todoroff K, Bhanegaonkar A, et al. Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study. Current Oncology. 2025. doi:10.3390/curroncol32040187
BibTeX
@article{Sura2025,
author = {Sura, Sneha and Bupathi, Manojkumar and Morris, Valerie and Conkling, Paul and Todoroff, Karen and Bhanegaonkar, Abhijeet and Ike, Chiemeka},
title = {Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32040187}
}
EUVIMED